The company
Ocular Therapeutix, Inc.
OCUL · Nasdaq
OCUL stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 28.5% below that average now. Biotechnology: 17% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 27% (−6 points in four weeks).
Statistics
- Last close, 22 Oct 2026
- 6.61 +2.01%
- 52-week range
- —
- Volume
- 2.15M
- Average volume (50 days)
- —
- Relative volume
- —
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 17% -9 in 4 wk
- Insider buys, 12 months
- $923K
- Insider sales, 12 months
- $5.7M
- Officials’ trades on record
- 0
- Institutions holding
- 250 (-8)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Price and volume
Daily bars to 22 Oct 2026: 29 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Todd AndermanChief Legal Officer | sold | 11,984at $7.29 | 8 Oct 2026filed 13 Oct 2026 |
| Jeffrey S. HeierChief Scientific Officer | sold | 10,869at $7.05 | 2 Oct 2026filed 6 Oct 2026 |
| Peter KaiserChief Development Officer | sold | 9,990at $7.05 | 2 Oct 2026filed 6 Oct 2026 |
| Donald NotmanChief Operating Officer | sold | 1,099at $10.24 | 31 Aug 2026filed 2 Sep 2026 |
| Pravin DugelDirector, Officer | sold | 21,649at $10.77 | 24 Aug 2026filed 26 Aug 2026 |
| Jeffrey S. HeierChief Scientific Officer | sold | 3,296at $10.78 | 24 Aug 2026filed 26 Aug 2026 |
| Sanjay NayakChief Strategy Officer | sold | 1,897at $10.78 | 24 Aug 2026filed 26 Aug 2026 |
| Peter KaiserChief Development Officer | sold | 3,035at $10.77 | 24 Aug 2026filed 26 Aug 2026 |
| Nadia WaheedChief Medical Officer | sold | 14,828at $8.27 | 3 Jun 2026filed 5 Jun 2026 |
| Sanjay NayakChief Strategy Officer | sold | 1,858at $8.20 | 26 May 2026filed 28 May 2026 |
| Jeffrey S. HeierChief Scientific Officer | sold | 3,018at $8.20 | 26 May 2026filed 28 May 2026 |
| Peter KaiserChief Development Officer | sold | 2,967at $8.20 | 26 May 2026filed 28 May 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 32,844,043$322.5M | +190,279+0.6% |
| Deep Track Capital, LPunchanged · filed 14 Aug 2026 | 19,686,282$193.3M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 19,376,555$190.3M | +3,243,624+20.1% |
| Avoro Capital Advisors LLCadded · filed 14 Aug 2026 | 12,540,000$123.1M | +225,000+1.8% |
| Summer Road LLCadded · filed 10 Aug 2026 | 12,208,296$119.9M | +328,471+2.8% |
| Venrock Adviser, LLCunchanged · filed 14 Aug 2026 | 10,346,926$101.6M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 8,832,595$86.7M | +113,556+1.3% |
| Logos Global Management LPadded · filed 14 Aug 2026 | 5,300,000$52.0M | +1,450,000+37.7% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 5,233,282$51.4M | +524,863+11.1% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 5,021,092$49.3M | +491,907+10.9% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.